Humacyte Medical Affairs
Publications
Clinical Publications
Civilian Vascular Injury Outcomes
Moore EE, Curi M, Namias N, Kundi R, Lum YW, Fox CJ, Rajani RR, Rasmussen TE, Sokolov O, Niklason LE, Khondker Z, Parikh SJ. Bioengineered human arteries for the repair of vascular injuries in an extremity injury subset of trial participants. JAMA Surg. 2025;160(2):181-189.
Read NowCivilian Vascular Injury, Long-Term Outcomes
Curi MA, Moore EE, Namias N, Kundi R, Lum YW, Fox CJ, Goldin I, Bou-Ghannam S, Berdugo M, Khondker Z, Parikh S, Niklason LE. Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair. J Vasc Surg Cases Innov Tech. 2026;12(1):102042.
Read NowCivilian and Military Vascular Injury - Propensity Matched to PROOVIT Registry
Rajani RR, Velez FF, Knight T, Kauffman L, Pascarella L, Malone DC, Rasmussen TE, Niklason LE, Parikh S. Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury. Trauma Surg Acute Care Open. 2025;10(4):e001814.
Read NowMilitary Vascular Injury, Long-Term Outcomes
Parikh S, Sokolov O, Shaprynskyi V, Skupyy O, Stanko O, Yurets S, Yurkova Y, Fadri M, Niklason L. Evaluating the safety and efficacy of Humacyte acellular tissue-engineered vessel in a real-world combat setting: a retrospective observational multicenter study. Mil Med. 2025;190(Suppl 2):288-296.
Read NowMilitary Vascular Injury, Real-World Use
Sokolov O, Shaprynskyi V, Skupyy O, Stanko O, Yurets S, Yurkova Y, Niklason LE. Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine-Russia conflict. Lancet Reg Health Eur. 2023;29:100650.
Read NowCivilian Hospital-Acquired Vascular Injury, Long-Term Outcomes
Lum YW, Moore EE, Kundi R, Morrison J, Shores JT, Niklason LE, Parikh S. Bioengineered human blood vessels to treat hospital-acquired vascular complications. J Vasc Surg Cases Innov Tech. 2025;11(6):101976.
Read NowScientific Publications
Low Susceptibility to Infection
Wang J, Blalock SKF, Levitan GS, Prichard HL, Niklason LE, Kirkton RD. Biological mechanisms of infection resistance in tissue engineered blood vessels compared to synthetic expanded polytetrafluoroethylene grafts. JVS Vasc Sci. 2023 Jul 14;4:100120. doi:10.1016/j.jvssci.2023.100120.
Read NowCell Repopulation and Remodeling
Kirkton RD, Santiago-Maysonet M, Lawson JH, Tente WE, Dahl SLM, Niklason LE, Prichard HL. Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation. Sci Transl Med. 2019;11(485):eaau6934. doi:10.1126/scitranslmed.aau6934.
Read NowPlease be advised that the documents you are accessing are provided for informational and educational purposes only. These documents are not intended to promote any product nor to be representative of all available information on the subject matter of your inquiry. The content is not to be modified, distributed or presented.
I UnderstandHumacyte® Medical Affairs
You are entering a website that is technical in nature and was created for scientific exchange with U.S. healthcare professionals. The content on this website may include scientific information about investigational biologic products or indications that are not approved. Humacyte does not support, endorse, or recommend the unapproved use of any biologic product including those discussed on this website.
Are you a U.S. healthcare professional licensed to practice in the United States?